AMZNprintsminutestrendsdividendsdrawdownsP/E 28.4macronarrativesvolatilitybuybackssentiment+0.8%marginsMSFTPMI 52.1momentumdividendsflowsPMI 52.1digeststhreadsvolatilityearnings callsvolumesβ 1.24breakoutsnewsflow2s10sliquidityheadlines−1.2%breakoutsnoiseGOOGLbuybacksrevisionstrendsPMI 52.1briefstickersnoiseGDPsentimentchattertranscriptsGOOGLsentimentvolatilitybuybacksMSFTwhispersMETAsessionsyield curves13FfuturesdowngradesPMI 52.1headlinesthe tapeflowsdowngradesfutures+0.8%earnings callstranscriptsclosesgammacatalystsrevisionsvolatilitysentimentchatter+2.41%earnings callssentimentfilingstrends10y 4.21%cyclesbuybackswiresspx 0dtewhisperstickersQ3trendsnewsflowearnings callsWTI 78.2sentimentnoisethreadsrumorsnarrativesFOMCconsensusestimatesmomentumYoY +18%tickersmomentumprintsβ 1.24revisions

momentumheadlines52w hipositioning2s10sfilingstrendsprintstrendsmacrocyclesnoise2s10smacroQ3narrativesheadlinesflowscyclesnarrativesspreadstranscriptsdowngradesupgradeswhisperswhispersminutesthe tapeNDXfuturesminutesyield curves52w hithe tapeFOMCcatalystsbriefsthe tapeNVDAguidancetrends52w hidrawdowns2s10swhispersmomentumdrawdownsbuybacks

PCEliquiditysentimentbreakoutsdowngradesP/E 28.4threadsAAPLSPXvolatilityNDXflowscyclesliquidityestimatesEPS 4.12

ADCT · NYSE · Biotechnology

ADC Therapeutics (ADCT)

Develops and sells ZYNLONTA while pursuing broader lymphoma use.

$1.32

Pre-market−0.01 (−0.38%)

At close$1.33(+7.29%)

Watchlist

In millions of USD, except per-share figures

In millions	Q3 FY23Sep 2023	Q4 FY23Dec 2023	Q1 FY24Mar 2024	Q2 FY24Jun 2024	Q3 FY24Sep 2024	Q4 FY24Dec 2024	Q1 FY25Mar 2025	Q2 FY25Jun 2025	Q3 FY25Sep 2025	Q4 FY25Dec 2025	Q1 FY26Mar 2026	Q2 FY26Jun 2026
Revenue	14	17	18	17	18	17	23	19	16	23	20	19
Cost of revenue	0	125	3	1	1	1	2	1	1	2	4	2
Gross profit	14	−108	16	16	18	16	21	18	15	21	16	17
	52	−68	49	45	53	48	49	62	46	39	42	42
Research & development	28	30	26	24	33	27	29	30	27	18	20	17
	23	25	23	21	21	21	−1	19	19	21	23	22
Selling & marketing	8	14	6	5	5	6	−11	4	5	6	13	13
General & administrative	15	11	18	16	16	15	10	15	14	16	10	10
Other expenses	0	−124	0	0	0	0	21	13	0	0	−1	3
Operating income	−37	−40	−34	−29	−36	−32	−28	−44	−30	−18	−25	−25
	−10	−2	−13	−7	−8	1	−10	−11	−11	11	−8	9
Interest income	3	3	3	3	3	3	2	2	2	2	2	2
Interest expense	13	8	12	13	13	12	12	13	13	13	12	14
Other non-operating income	−4	−6	0	−6	−5	−13	−2	−2	−3	−24	−5	21
Income before tax	−48	−42	−46	−36	−44	−31	−38	−55	−41	−7	−33	−17
Income tax expense	0	43	0	0	0	0	0	1	0	0	0	0
Net income from continuing operations	−48	−85	−47	−37	−44	−31	−39	−57	−41	−6	−33	−17
Net income	−48	−85	−47	−37	−44	−31	−39	−57	−41	−6	−33	−17
EPS, basic	−$0.58	−$1.03	−$0.56	−$0.38	−$0.42	−$0.29	−$0.36	−$0.50	−$0.30	−$0.04	−$0.21	−$0.11
EPS, diluted	−$0.58	−$1.03	−$0.56	−$0.38	−$0.42	−$0.29	−$0.36	−$0.50	−$0.30	−$0.04	−$0.21	−$0.11
Weighted average shares, basic	82	82	83	96	105	105	107	114	136	150	154	155
Weighted average shares, diluted	82	82	83	96	105	105	107	114	136	150	154	155
EBITDA	−33	−34	−32	−22	−30	−19	−26	−42	−27	6	−20	−46
Depreciation & amortization	1	0	1	1	1	1	1	1	0	0	0	0
EBIT	−34	−34	−33	−23	−31	−20	−26	−42	−28	6	−21	−46